Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J
Lucid Diligence Brief: MeiraGTx re-acquires bota-vec rights from J&J…
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in Sarcoma
Lucid Diligence Brief: STORM Therapeutics $56 million Series C for Phase II in…
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas
Lucid Diligence Brief: Vir Biotechnology $1.37B collaboration with Astellas…
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration
Lucid Diligence Brief: Telix / Regeneron radiopharma collaboration Professional…
Lucid Diligence Brief: Anthropic acquires Coefficient Bio
Lucid Diligence Brief: Anthropic acquires Coefficient Bio Professional…
Lucid Diligence Brief: Insight Health $11 million Series A to focus on AI clinical agents
Lucid Diligence Brief: Insight Health $11 million Series A to focus on AI…
Lucid Diligence Brief: Stipple Bio $100 million Series A
Lucid Diligence Brief: Stipple Bio $100 million Series A Professional audiences…
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B
Lucid Diligence Brief: Syneron Bio completion of $150 million Series B…
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals
Lucid Diligence Brief: Eli Lilly acquires Centessa Pharmaceuticals Professional…
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1 asset
Lucid Diligence Brief: Ambrosia Biosciences $100M Series B for oral GLP-1……